Drug intelligence / Profile preview

RMP-402

Development stage: Preclinical
Lead developer: RxMP Therapeutics
Modality: Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

RMP-402 is a first-in-class hemostatic therapeutic developed by RxMP Therapeutics for the treatment of severe hemorrhage and trauma-induced coagulopathy. The drug consists of chemically modified, red blood cell-derived microparticles (RxMPs) that provide a highly procoagulant surface to accelerate the body's natural clotting process. By facilitating the assembly of the prothrombinase complex (Factors Xa and Va) and enhancing thrombin generation at the site of vascular injury, RMP-402 aims to stop life-threatening bleeding more effectively than current standards of care. As of 2024, the program is in late preclinical development, with OrganaBio serving as the cGMP manufacturing partner for IND-enabling studies.

Beyond the preview

Go deeper on RMP-402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMP-402.

Explore the full profile